Richard A. Silfen practices in the area of corporate law with concentrations in securities and mergers and acquisitions. Mr. Silfen advises publicly traded companies in connection with public and private debt and equity securities offerings. He also advises companies with regard to mergers and acquisition transactions. Mr. Silfen also advises clients in connection with private equity investments in publicly traded and privately owned issuers, senior, high-yield, mezzanine and other debt issuances using complex structures and restructurings of multi-layer debt.

In addition, Mr. Silfen assists emerging and other businesses to develop plans for the growth and development of their businesses and technologies, including financing transactions, collaborative and strategic partnerships, and joint venture arrangements. Mr. Silfen also works with clients to facilitate public reporting and analysis of operating results, advises on internal audit functions and other Sarbanes-Oxley compliance, and works with clients to support and enhance strategies for communication with security analysts and investors.

Mr. Silfen is a 1987 graduate of the University of Alabama School of Law and a graduate of Baylor University.

Areas Of Practice

Corporate and Securities
Mergers and Acquisitions
Corporate Law

Representative Matters

Mergers & Acquisitions

Represented a NASDAQ 100 international biopharmaceutical company in making an unsolicited proposal to acquire a NASDAQ-traded biopharmaceutical company that had announced entry into a merger agreement with a strategic acquirer. The unsolicited proposal led to the termination of the merger agreement and the subsequent acquisition by the international biopharmaceutical company for a cash purchase price in excess of $500 million.
Represented a NASDAQ 100 international biopharmaceutical company in the formation of a $100 million joint venture to fund marketing and other commercial activities for certain of its proprietary marketed products.
Represented a NASDAQ 100 international biopharmaceutical company in its proposed acquisition of an Australian Stock Exchange-traded company that marketed a novel, proprietary cancer therapeutic product through a cash takeover bid valued in excess of US$150 million.
Represented a leading NYSE-traded international real estate investment trust (REIT) in its efforts to make an approximately $2.5 billion cash acquisition of a NYSE-traded industrial REIT.
Represented a leading NYSE-traded international REIT in its efforts to merge with a suburban office REIT in a transaction valued in excess of $13 billion.
Represented a leading global provider of centralized core-diagnostic electrocardiographic (ECG) services to the pharmaceutical, biotechnology and medical device industries in its approximately $50 million cash acquisition of a complementary business from a NYSE-traded CRO and its related entry into an exclusive 10-year marketing agreement for the seller to offer its clients the acquirer's services.
Represented a NYSE-traded specialty REIT in its formation and approximately $70 million private equity capital raise to fund its launch and initial acquisitions of properties.
Represented a NASDAQ-traded developer of advanced technology medical molecular diagnostic products in its approximately $60 million acquisition of the NASDAQ-traded developer and marketer of proprietary genomic and molecular diagnostics products.
Represented a NASDAQ-traded developer of advanced technology medical molecular diagnostic products in its acquisition of the Toronto Stock Exchange-traded developer and marketer of point-of-care medical molecular diagnostic tests.
Represented a NASDAQ-traded owner and operator of private schools in its private equity-backed, management-led "going private" leveraged buyout transaction.
Represented a NASDAQ-traded global industrial automation software company in its sale to an Israeli, NASDAQ-traded software company.
Represented a NASDAQ-traded provider of business technology software for the durable goods distribution market in its approximately $70 million sale to two private equity groups.
Advised a leading NYSE-traded international REIT in its approximately $900 million acquisition of a NYSE-traded REIT.

Capital Markets Transactions

Represented pharmaceutical, biopharmaceutical and biotechnology companies in securities offerings raising in excess of $5 billion of debt, equity and convertible securities, including senior debt, mezzanine and other subordinated debt, securities issued in connection with derivative trading strategies and equity-linked securities, in registered and private transactions.
Represented a NYSE-traded suburban office and industrial REIT in public offerings of common shares, preferred shares and debt securities raising in excess of $5 billion.
Represented a NYSE-traded specialty REIT focused on student housing and military housing in its approximately $350 million initial public offering.
Represented a NASDAQ-traded biomaterials company in the issuance of $45 million of mezzanine debt, restructuring the company's balance sheet and providing access to growth capital.
Represented a NASDAQ-traded biomaterials company in an approximately $35 million investment by a private equity group.
Represented a NYSE-traded mid-Atlantic-based suburban office REIT in securities offerings of common shares, preferred shares and debt securities raising in excess of $300 million.
Represented the founder and controlling stockholder of a NYSE-traded REIT specializing in the ownership and operation of neighborhood and community shopping centers in its initial public offering raising approximately $450 million.
Represented a NYSE-traded, leading provider of water and wastewater utility services throughout the United States in registered securities offerings raising in excess of $300 million.
Represented a NYSE-traded owner and operator of one of the largest independent refined petroleum products pipeline systems in the United States in its 144A offering $150 million of notes.
Represented a NASDAQ-traded owner and operator of private schools in connection with investments made by a private equity group and efforts to restructure the PEG investment.

Admissions

Pennsylvania
Florida

Education

The University of Alabama School of Law, J.D., 1987
Baylor University, B.A., 1983

Experience

Duane Morris LLP
- Partner, 2007-present
Cangen Biotechnologies, Inc.
- President and Chief Financial Officer, 2004-2006
Morgan, Lewis & Bockius LLP
- Partner, 2000-2004
Wolf, Block, Schorr and Solis-Cohen LLP
- Vice Chairman, Corporate Department, 1999-2000
- Partner, 1996-2000

Board Memberships

GMH Communities Trust
- Chairman, Nominating and Governance Committee of Board of Trustees
- Chairman, Special Committee of the Board of Trustees, 2006
- Chairman, Nominating and Governance Committee of the Board of Trustees, 2004-present
- Member, Audit Committee of the Board of Trustees, 2004-present

Selected Publications

Author, "Due Diligence Review of Internal Controls: Focusing Beyond the Numbers," Deal Lawyers, November-December 2007

Selected Speaking Engagements

Moderator, "Biotech Perspective's on Key Considerations for Structuring a Winning Deal" panel, Pharmaceutical Collaboration and Transaction Accounting Conference, September 18, 2007
Speaker,"Internal Controls: The Latest Developments," Society of Corporate Secretaries & Governance Professionals Mid-Atlantic Chapter ? Annual Meeting Program, Philadelphia, Pennsylvania, May 21, 2007